DRUG PRESCRIPTION OF MIGRAINE MANAGEMENT
Abstract
Introduction : Migraine, a common neurological disorder characterised by throbbing pain or pulsating sensation usually
on one side of the head. Common symptoms that occur during the episode includes visual disturbance, nausea and
photophobia. ] Migraine may progress with four stages like prodrome, aura, headache and post –drome. Migraine became the fourth leading
cause to visit the emergency department and accounting to 3.1 % of all emergency visits from 2009-2010.Therefore, the present study was
carried to identify the rational use of drugs in management and prevention of acute and chronic migraine.
Objectives: The aim of the study is the drug prescription pattern of migraine management
Materials and method: The present study is a prospective, cross sectional and observational study carried in the outpatient Department of
Neurology in collaboration with the department of neurology.it is a prospective study.
Result: About 624 patients who attended the outpatient department of Neurology with proper inclusion criteria were included as subjects for the
study. Out of 624 patients, 336 were female and 288 were male patients. Average age of female patients was 37 years, male patients was 39 years
and average age of the population attending the outpatient department of Neurology was 44 years.
Discussion and Conclusion: the commonest complaint which with patients come to OPD with headache. the study with female population of
53% and male is 57%. The most common precipitants in this study were travel (78.02%), tension, hunger/ skipped meal/ fasting, insomnia,
depression etc. Triptans are consider as first line therapy of moderate to severe attack or mild to moderate attack. The drug flunarizine is most
used drug for patients for almost 224. because of its less side effects and easily available calcium channel blocker. Migraine is commonly
increasing now a days, people affected are more likely to be male. The medications that are mostly prescribed are NSIAD'S and flunarizine
because of its easier availability.
Keywords
Full Text:
PDFReferences
Hansen JM, Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Goadsby PJ, Charles A. Migraine headache is present in the aura phase: a prospective study. Neurology. 2012 Nov 13;79(20):2044-9.
Carmona S, Bruera O. Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update. Therapeutics and clinical risk management. 2009;5:661.
Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, Macrae A. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003 Mar 25;60(6):935-40.
Al-Shimmery EK. Precipitating and relieving factors of migraine headache in 200 iraqi kurdish patients. Oman medical journal. 2010 Jul;25(3):212.
Agosti R. Migraine Burden of Disease: From the Patient's Experience to a Socio‐Economic View. Headache: The Journal of Head and Face Pain. 2018 May;58:17-32.
Ray BK, Paul N, Hazra A, Das S, Ghosal MK, Misra AK, Banerjee TK, Chaudhuri A, Das SK. Prevalence, burden, and risk factors of migraine: A community-based study from Eastern India. Neurology India. 2017 Nov 1;65(6):1280. Burch RC, Loder S, Loder E, Smitherman TA. The Prevalence and Burden of Migraine and Severe Headache in the U nited S tates: Updated Statistics From Government Health Surveillance Studies. Headache: The Journal of Head and Face Pain. 2015 Jan;55(1):21-34.
Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatric disease and treatment. 2006 Sep;2(3):281
Brahma D, Marak M, Wahlang J. Rational use of drugs and irrational drug combinations. The Internet J Pharmacol. 2012;10(1):14081
Ofori-Asenso R, Agyeman A. Irrational use of medicines—a summary of key concepts. Pharmacy. 2016 Dec;4(4):35.
Sproul J, MacCallum J, Ledger S. Screens and teens with migraines: visually sensitive learners in contemporary digital classrooms. Disability & Society. 2017 Sep 14;32(8):1275-9.
S. N. Malik, M. Hopkins, W. B. Young, and S. D. Silberstein, “Acute migraine treatment: patterns of use and satisfaction in a clinical population,” Headache, vol. 46, no. 5, pp. 773–780, 2006.
Beckham EE, Watkins JT. Process and outcome in cognitive therapy. InComprehensive handbook of cognitive therapy 1989 (pp. 61-81). Springer, New York, NY.
Martin PR, MacLeod C. Behavioral management of headache triggers: Avoidance of triggers is an inadequate strategy. Clinical psychology review. 2009 Aug 1;29(6):483-95.
Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2006 Apr;59(4):652-61.
Keam SJ, Goa KL, Figgitt DP. Almotriptan. Drugs. 2002 Feb 1;62(2):387-414
Láinez MJ, García-Casado A, Gascón F. Optimal management of severe nausea and vomiting in migraine: improving patient outcomes. Patient related outcome measures. 2013;4:61.
Deleu D, Hanssens Y. Guidelines for the prevention of migraine. Neurosciences. 2000 Jan;5(1):7-12.
Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PloS one. 2015 Jul 14;10(7):e0130733.
Refbacks
- There are currently no refbacks.